N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open

The Lancet Respiratory Medicine

Volumn 5, Issue 1, 2017, Pages e1-e2

  Raghu, Ganesh ^a   Noth, Imre ^b   Martinez, Fernando ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Cornell University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; PIRFENIDONE; PLACEBO;

DRUG EFFICACY; DRUG TOLERABILITY; FIBROSING ALVEOLITIS; GENOTYPE; HUMAN; LETTER; MONOTHERAPY; PHARMACOGENOMICS; PRIORITY JOURNAL; VITAL CAPACITY; INHALATIONAL DRUG ADMINISTRATION; LUNG FIBROSIS;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PULMONARY FIBROSIS; VITAL CAPACITY;

EID: 85006321347     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30327-7     Document Type: Letter

References (9)

1. 1 Behr, J, Bendstrup, E, Grestani, B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med 4 (2016), 445–453.
2. 2 Noble, Pw, Albera, C, Bradford, WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (Capacity): two randomised trials. Lancet 377 (2011), 1760–1769.
3. 3 Wijsenbeek, MS, Collard, HR, Acetylcysteine in IPF: the knockout blow?. Lancet Respir Med 4 (2016), 420–421.
4. 4 Martinez, FJ, de Andrade, JA, Anstrom, KJ, King, TE Jr, Raghu, G, for the idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2093–2101.
5. 5 Johnson, WC, Raghu, G, Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures. Eur Respir J 26 (2005), 755–758.
6. 6 King, TE Jr, Albera, C, Bradford, WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (inspire): a multicentre, randomised, placebo-controlled trial. Lancet 374 (2009), 222–228.
7. 7 King, TE Jr, Brown, KK, Raghu, G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 92–99.
8. 8 Raghu, G, Rochwerg, B, Zhang, Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Resp Crit Care Med 192 (2015), e3–19.
9. 9 Oldham, JM, Ma, SF, Martinez, FJ, et al. TOLLIP, MUC5B and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 192 (2015), 1475–1482.